Skip to main content

Table 1 Socio-demographics and disease characteristics of participants and non-participants

From: Health related quality of life and parental perceptions of child vulnerability among parents of a child with juvenile idiopathic arthritis: results from a web-based survey

 

Participants

Non-participants

 

PARENTS

N

M

SD

N

M

SD

 

Age (years)

155

41.99

5.40

    
 

N

%

 

N

%

 

p

Country of birth parents (Netherlands)

139

83.7

 

65

61.9

 

<.001b

Gender (female)

147

87.5

     

Married/living together

158

94.0

     

Education

       

 Low

22

13.1

     

 Middle

86

51.2

     

 High

60

35.7

     

Number of children

       

 1

22

13.1

     

 2-3

135

80.3

     

 > 3

11

6.6

     

CHILDREN

N

M

SD

N

M

SD

p

Age (years)

168

11.48

4.56

105

13.28

3.87

<.001a

Age of disease onset

165

7.40

4.42

104

8.61

4.46

.03a

Age of diagnosis

168

8.58

4.69

103

9.72

4.52

.05a

 

N

%

 

N

%

 

p

Gender (female)

113

67.3

 

65

61.9

 

.34b

JIA subtype

N

%

 

N

%

 

p

 Oligo-articular JIA, persistent

40

13.8

 

19

18.1

 

.26b

 Oligo-articular JIA, extended

21

12.5

 

12

11.4

 

.79b

 Poly-articular JIA, RF negative

66

39.4

 

46

43.8

 

.46b

 Poly-articular JIA, RF positive

5

3.0

 

4

3.8

 

.71b

 Systemic JIA

7

4.2

 

3

2.9

 

*

 Enthesitis related Arthritis

18

10.7

 

11

10.5

 

.95b

 Undifferentiated JIA

9

5.3

 

8

7.7

 

.50b

 Chronic arthritis with other autoimmune inflammatory disease

2

1.2

 

2

1.9

 

*

 

N

Median (range)

N

Median (range)

p

  

Time between symptom onset and diagnosis of JIA (months)

165

0.55 (0–8.78)

102

0.47 (0.1-10.26)

  

.19c

Disease duration (years)

165

3.46 (0.28-14.82)

102

3.77 (0.45-14.13)

  

.15c

Physician disease activity (VAS score range 0–100)

165

15.00 (0–84)

102

17.00 (0–94)

  

.85c

Number of joints with arthritis

N

%

 

N

%

 

p

No arthritis

76

45.2

 

46

43.8

 

.82b

 Monoarthritis (1 joint)

21

12.5

 

18

17.1

 

.29b

 Oligoarthritis (2–4 joints)

45

26.8

 

22

21.0

 

.28b

 Polyarthritis (>4 joints)

23

13.7

 

19

18.1

 

.57b

 Uveitis presenting during disease course

8

4.8

 

9

8.6

 

.45b

Medication at time point of evaluation

N

%

 

N

%

 

p

 No medication

13

7.7

 

16

15.2

 

.05b

 NSAID

98

58.3

 

47

44.8

 

.029b

 DMARDS (including methotrexate, sulfasalazine)

131

78.0

 

76

72.4

 

.38b

 Anti-TNF

24

14.3

 

1

9.5

 

*

 DMARDS and Biological (Anti-TNF)

21

12.5

 

9

8.6

 

.31b

  1. a = independent samples T-test, b = Chi2, c = Mann-Whitney U test, * = less than 5 cases in a cell.
  2. Abbrevations: JIA = Juvenile Idiopathic Arthritis, VAS = Visual Analogue Scale, NSAID = Non Steroid Anti-Inflammatory Drug, DMARD = Disease Modifying Anti-Rheumatic Drug: methotrexate, sulfasalazine, Anti-TNF = anti-Tumor Necrosis Factor: etanercept, adalimumab, infliximab.